Trial Profile

Phase 2a 12 week U.S.-based, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ECC 4703, ECC 0509, and the combination of the two in adults with presumed metabolic dysfunction-associated steatohepatitis (MASH)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Nov 2025 New trial record
06 Oct 2025 According to Eccogene media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for this MOSAIC trial

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com